Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | ABCB1 | P08183 | 4/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | F13A1 | P00488 | 1/20 | 0.36 |
| ▸ | TGM2 | P21980 | 1/20 | 0.36 |
| ▸ | TGM1 | P22735 | 1/20 | 0.36 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.36 |
| ▸ | MAOA | P21397 | 2/20 | 0.36 |
| ▸ | CCR4 | P51679 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | KDM1A | O60341 | 1/20 | 0.35 |
| ▸ | DRD2 | P14416 | 1/20 | 0.35 |
| ▸ | DRD3 | P35462 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2452755 | 0.85 | MAOA (0.40) | F13A1TGM2TGM1GPR119MAOA | |
| SCHEMBL2479908 | 0.85 | MAOB (0.48) | MAOAMAOB | |
| SCHEMBL2503392 | 0.85 | GPR119 (0.37) | KDM4EPKMF13A1TGM2TGM1 | |
| SCHEMBL2480116 | 0.83 | ALDH1A1 (0.37) | KDM4EGPR119MAPT | |
| SCHEMBL2486343 | 0.82 | GPR119 (0.37) | F13A1TGM2TGM1GPR119 | |
| SCHEMBL2507043 | 0.81 | GPR119 (0.41) | KDM4EGPR119MAPT | |
| SCHEMBL2480377 | 0.80 | GPR119 (0.40) | KDM4EGPR119MAOAMAPT | |
| SCHEMBL2499942 | 0.79 | GPR119 (0.39) | F13A1TGM2TGM1GPR119 | |
| SCHEMBL2504488 | 0.79 | ABCB1 (0.40) | ABCB1HDAC1GPR119MAPT | |
| SCHEMBL2498576 | 0.77 | HPGD (0.39) | KDM4EGPR119MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8841306-B2 | Antimicrobials | PANACEA BIOTEC LTD. (IN) | 2014-09-23 | — | — | US | disclosed |
| US-20110245258-A1 | NOVEL ANTIMICROBIALS | PANACEA BIOTEC LTD. (IN) | 2011-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245258-A1 | NOVEL ANTIMICROBIALS | ECI1, XDH, CYP3A4 | KDM4E 4158/4885PKM 382/4885ABCB1 448/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.